Korea Research and Globizz Sign Strategic Business Agreement for FDA Approval

On the 26th, Korea Research , a comprehensive market research company, signed a strategic business agreement (MOU) with Globizz , a world leader in global FDA consulting, to provide a full range of services for FDA approval of medical devices. The two organizations agreed to pursue cooperation to provide services encompassing usability and regulatory science (RA) to global medical device companies.

This agreement aims to provide services for usability assessment and regulatory-related tasks for not only Korean medical device companies entering the US market, but also medical device companies in the Asia-Pacific region entering the US market, through collaboration between Korea Research Innovation Division, which possesses the best global UX research and usability evaluation capabilities in Korea, and Globizz, which provides FDA approval consulting in multiple countries including Korea, Japan, and India, centered around the US.

“The excellent research capabilities and international work experience of the Medical Device Usability Assessment Center of the Innovation Division are highly competitive not only in Korea but also in the Asia-Pacific region,” said Kang Deok-yong, head of the Innovation Division of Korea Research. “Through this business agreement, Korea Research has completed building global capabilities that can provide professional services in all areas from the first to the last stage of medical device development.”

“Through our collaboration with Korea Research Innovation Headquarters, we are looking at not only Korean medical device companies but also the entire Asia-Pacific region together,” said Takahiro Haruyama, CEO of Globizz. “Through this agreement, we will be able to effectively deploy our licensing expertise and experience in the medical device field.”

The two organizations plan to provide a variety of services tailored to the needs of medical device companies in the Asia-Pacific region preparing for FDA approval for future entry into the U.S. market.

• See more related articles